Topoisomerase II Inhibitor
Combination Therapy for Acute Lymphoblastic Leukemia
Recruiting3 awardsPhase 2
Boston, Massachusetts
This trial will study a new multi-drug chemotherapy regimen for treating Acute Lymphoblastic Leukemia in adults. The regimen includes drugs that have been used to treat pediatric patients in the past, as well as new drugs PEG-asparaginase and E. coli asparaginase. Researchers hope to learn more about the disease and how it responds to standard chemotherapy drugs.
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Burbank, California
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitors for Hypereosinophilic Syndrome
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is for patients with a rare blood disorder called hypereosinophilic syndrome, who have not responded to standard treatment. The study will test whether the drug imatinib mesylate (Gleevec) is safe and effective in reducing blood eosinophils in these patients.
Tyrosine Kinase Inhibitor
Asciminib Combinations for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Augusta, Georgia
This trial tests the effectiveness and safety of a medication called asciminib in patients newly diagnosed with Chronic Myeloid Leukemia in the Chronic Phase. Patients will take asciminib daily, and if they do not respond after a few years, they may also take another low-dose medication. Asciminib works by blocking a protein that helps cancer cells grow.
Popular Filters
Trials With No Placebo
Tyrosine Kinase Inhibitor
Ruxolitinib + Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial will compare the different tyrosine kinase inhibitors, with and without ruxolitinib, to see how well they work in treating patients with chronic myeloid leukemia.
Topoisomerase II Inhibitor
Imatinib + Chemotherapy for Acute Lymphoblastic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial tests how well the drug imatinib works with different chemotherapy treatments for patients with specific types of leukemia. It aims to find out if a less intense chemotherapy regimen can be as effective as a stronger one but with fewer side effects. The study focuses on patients with certain types of acute lymphoblastic leukemia.
MEK Inhibitor
MEK162 + Imatinib for Gastrointestinal Stromal Tumor
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing the effects of two drugs, MEK162 and imatinib, on Gastrointestinal Stromal Tumor (GIST). The funding for this trial comes from the FDA Office of Orphan Products Development and Array/Pfizer.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.